Hwaseong-si, South Korea

Jung Soo Nam


Average Co-Inventor Count = 8.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations of Jung Soo Nam in Pharmaceutical Chemistry

Introduction

Jung Soo Nam is a notable inventor based in Hwaseong-si, South Korea. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that target specific biological pathways. His work focuses on innovative solutions for treating diseases linked to abnormal enzyme activity.

Latest Patents

Jung Soo Nam holds a patent for "Imidazopyridine derivative compounds and use of same." This patent describes a compound selected from a chemical formula that exhibits lysine-specific demethylase-1 (LSD1) inhibitory activity. The compound is effective in preventing or treating diseases caused by the abnormal activation of LSD1. Additionally, the patent discloses a composition containing the compound as an active ingredient, highlighting its potential therapeutic applications.

Career Highlights

Jung Soo Nam is currently associated with Hanmi Pharmaceutical Co., Ltd., a leading company in the pharmaceutical industry. His role involves research and development of innovative drug compounds that can address unmet medical needs. His expertise in medicinal chemistry has positioned him as a valuable asset in the field.

Collaborations

Jung Soo Nam has collaborated with notable colleagues, including In Hwan Bae and Won Jeoung Kim. These collaborations have fostered a productive research environment, leading to advancements in their shared field of study.

Conclusion

Jung Soo Nam's contributions to pharmaceutical chemistry, particularly through his patent on Imidazopyridine derivative compounds, demonstrate his commitment to innovation in medicine. His work continues to pave the way for new treatments that can significantly impact patient care.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…